Table 4.
Changes in triglycerides and HDL-cholesterol concentrations, and body-mass index by treatment groups, over the course of four visits
| Enalapril (n=1874) | Sacubitril/valsartan (n=1904) | Adjusted for screening values | ||
|---|---|---|---|---|
|
| ||||
| Difference (95% CI) | p value | |||
| Triglycerides (mmol/L) | ||||
|
| ||||
| Screening | 1·88 (1·56) | 1·79 (1·15) | ·· | ·· |
| 1-year | 1·93 (1·46) | 1·95 (1·52) | 0·08 (−0·01 to 0·17) | 0·094 |
| 2-year | 2·04 (1·82) | 1·87 (1·22) | −0·16 (−0·27 to −0·04) | 0·0083 |
| 3-year | 1·92 (1·28) | 1·84 (1·57) | −0·06 (−0·22 to 0·10) | 0·46 |
| Overall* | ·· | ·· | −0·01 (−0·09 to 0·07) | 0·83 |
|
| ||||
| HDL cholesterol (mmol/L) | ||||
|
| ||||
| Screening | 1·16 (0·34) | 1·15 (0·33) | ·· | ·· |
| 1-year | 1·15 (0·35) | 1·16 (0·35) | 0·01 (−0·01 to 0·02) | 0·50 |
| 2-year | 1·15 (0·34) | 1·17 (0·36) | 0·03 (0·01 to 0·05) | 0·0073 |
| 3-year | 1·15 (0·33) | 1·21 (0·38) | 0·06 (0·02 to 0·09) | 0·0011 |
| Overall* | ·· | ·· | 0·02 (0·00 to 0·03) | 0·043 |
|
| ||||
| BMI (kg/m2) | ||||
|
| ||||
| Screening | 29·01 (5·69) | 29·05 (5·87) | ·· | ·· |
| 1-year | 29·23 (5·70) | 29·58 (5·83) | 0·26 (0·13 to 0·40) | 0·0001 |
| 2-year | 29·07 (5·77) | 29·68 (5·72) | 0·31 (0·12 to 0·49) | 0·0012 |
| 3-year | 29·57 (6·07) | 29·65 (5·67) | 0·27 (−0·02 to 0·57) | 0·065 |
| Overall* | ·· | ·· | 0·28 (0·14 to 0·41) | <0·0001 |
Data are mean (SD).
*
Longitudinal model.